Blood Pressure Medication Recall Expands; Now Includes Losartan

If you are someone who takes medication for high blood pressure, you should be more careful nowadays. In addition to the existing recalls, more blood pressure medication drugs are being included in the recall that’s happening right now. According to the latest reports, Losartan has also been added to the list, making things worse for a lot of users. The recall is happening because authorities have found an ‘impurity’ in the drugs.
N-Nitroso-N-methyl-4-aminobutyric acid or NMBA is the name of the impurity that has been found in those blood pressure drugs being recalled. It is known to be one of the serious carcinogens that can affect animals including human beings. The basic idea that such an impurity has gotten into blood pressure medication has shaken many people who have been using these drugs.
“The U.S. Food and Drug Administration is updating the public on the agency’s ongoing investigation surrounding the recent voluntary recalls of multiple generic angiotensin II receptor blocker (ARB) drug products used to treat high blood pressure and heart failure. Hetero Labs Ltd. in India has announced a recall of 87 lots of losartan potassium tablets (25 mg, 50 mg and 100 mg),” reads the official press release.
It should be noted that the Losartan tablets were voluntarily recalled by Camber Pharmaceuticals, which is distributing the medication in the United States. Despite the recall, the company said that it has not received any complaint or other adverse news regarding the use of these tablets. It was found in recent testing that the levels of NMBA was higher than the acceptable limits set by FDA.
While FDA says that the impact on the individual is minimal, the significance of the issue can’t be overlooked in any way. Now, the agency is trying to make sure that no one is getting affected by these impurities and to ensure that the certification methods are made stronger in the future.

Show More

Jason Amato

Jason was appointed to a three-year term at in September 2015. Later he was continued as the chief editor of the publication. In his role, Jason serves as the public's representative to He is responsible for bringing transparency to matters of journalism and journalism ethics. receives tens and thousands of inquiries annually and the Jason responds to significant queries, comments, and criticisms. Jason has a decade of experience taking an objective at the media industry and this experience has helped her is expertizing business and health sectors. So, when it's about business and health news, Jason is the go-to guy at

Leave a Reply

Your email address will not be published. Required fields are marked *